New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference
October 02 2023 - 6:30AM
Vivos Therapeutics, Inc. (the “Company” or “Vivos”)
(NASDAQ:VVOS), a leading medical device and technology
company specializing in the development and commercialization of
highly effective, proprietary oral appliances for the treatment of
breathing-related sleep disorders, today announced that world
renowned author James Nestor will headline a multidisciplinary list
of distinguished speakers at the Company’s Fifth Annual Breathing
Wellness Conference. This year’s conference will be held October
26-28 in Puerto Vallarta, Mexico.
In his New York Times best-selling book, Breath,
Mr. Nestor chronicles his own fascinating journey of discovery and
healing. According to mrjamesnestor.com, “Modern research in
pulmonology, psychology, biochemistry, and human physiology is
showing us that making even slight adjustments to the way we inhale
and exhale can help jump-start athletic performance, rejuvenate
internal organs, halt snoring, allergies, asthma, and some
autoimmune disease, and even straighten spines. None of this
should be possible, and yet it is.”
That message is at the core of Vivos’ wide range
of product offerings and resonates with every one of the over 1,800
Vivos-trained dentists in the United States and Canada. Which makes
sense, since Vivos owns and offers the technology that Mr. Nestor
used successfully during his own personal treatment.
Joining Mr. Nestor as keynote speakers are
nationally renowned and best-selling authors Joe Sweeney and David
McCarty, MD, a board certified sleep specialist. Other conference
speakers and presenters include experts from a wide variety of
dental and medical disciplines such as cardiology, pediatrics,
specialty chiropractic, laser therapy, airway dentistry, and
practice management. Attendees will learn and experience firsthand
from both published scientific papers and individual cases how the
very latest concepts and treatment breakthroughs from Vivos are
yielding significantly improved clinical results in a shorter
treatment time.
Kirk Huntsman, Chairman and CEO of Vivos,
stated, “We are thrilled to host our Fifth Annual Breathing
Wellness Conference. This year’s conference will be primarily
user-focused, providing Vivos-trained doctors with our latest
updates and resources to help them better serve their patients.
This includes the multiple new services, products and technologies
we have recently added to our offerings, along with new advanced
training offerings that are simply unavailable anywhere else. For
us, the greatest satisfaction comes after the conference, as our
doctors go back and start implementing what they learned with
patients.”
About Vivos Therapeutics,
Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a
medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from breathing and sleep issues arising from
certain dentofacial abnormalities such as mild-to-moderate
obstructive sleep apnea (OSA) and snoring in adults. The Vivos
Method represents the first clinically effective nonsurgical,
noninvasive, nonpharmaceutical and cost-effective solution for
treating mild to moderate OSA. It has proven effective in
approximately 40,000 patients treated worldwide by more than 1,800
trained dentists.The Vivos Method includes the Vivos Complete
Airway Repositioning and/or Expansion (CARE) appliance therapy and
associated protocols that alter the size, shape and position of the
soft tissues that comprise a patient’s upper airway and/or palate.
The Vivos Method opens airway space and may significantly reduce
symptoms and conditions associated with mild-to-moderate OSA, such
as lowering Apnea Hypopnea Index scores. Vivos also markets and
distributes SleepImage diagnostic technology under its VivoScore
program for home sleep testing in adults and children. The Vivos
Integrated Practice (VIP) program offers dentists training and
other value-added services in connection with using The Vivos
Method.For more information, visit
www.vivos.com. Cautionary Note Regarding
Forward-Looking Statements This press release,
the conference referred to herein, and statements of the Company’s
management made in connection therewith contain “forward-looking
statements” (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended) concerning future events, particularly with
respect to the public offering described herein. Words such as
“may”, “should”, “expects”, “projects,” “intends”, “plans”,
“believes”, “anticipates”, “hopes”, “estimates”, “goal” and
variations of such words and similar expressions are intended to
identify forward-looking statements. These statements involve
significant known and unknown risks and are based upon several
assumptions and estimates, which are inherently subject to
significant uncertainties and contingencies, many of which are
beyond Vivos’ control. Actual results (including, without
limitation, any anticipated benefits to the Company of the
Breathing Wellness Conference as described herein) may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ
materially include, but are not limited to: (i) the risk that Vivos
may be unable to implement revenue, sales and marketing strategies
that increase revenues, (ii) risks associated with regulatory
scrutiny of and adverse publicity in the sleep apnea treatment
sector; (iii) the risk that Vivos may be unable to secure
additional financings on reasonable terms when needed, if at all
and (iv) other risk factors described in Vivos’ filings with the
Securities and Exchange Commission (“SEC”). Vivos’ filings can be
obtained free of charge on the SEC’s website at www.sec.gov. Except
to the extent required by law, Vivos expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Vivos’ expectations with respect thereto or
any change in events, conditions, or circumstances on which any
statement is based. Vivos Investor Relations
Contact: Julie Gannon Investor Relations
Officer 720-442-8113jgannon@vivoslife.com
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Apr 2024 to May 2024
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From May 2023 to May 2024